
ZEISS MyoCare lens portfolio
Clinically proven to effectively slow myopia progression.
ZEISS
Seeing beyond



Myopia moves fast.

It is predicted that 50% of the world's population may be myopic by 2050.[1]
Landmark study by Holden et al. in 2016.

The World Health Organization (WHO) reports that over **2.2 billion** people experience vision impairment, with more than **1 billion** of these cases being preventable.[2]

Myopia, the most common refractive error, has been identified as a global pandemic, particularly affecting children and adolescents due to increased near-work activities, screen time, and reduced outdoor exposure.

Myopia: Starting earlier, moving faster.


Recent studies indicate that myopia is beginning at an earlier age and progressing at a faster rate than ever before.[3] This early onset means that children experience myopia over an extended period, potentially leading to higher degrees of myopia, which can adversely affect their eye health.

Several factors contribute to the rapid increase in myopia prevalence. The individual progression rate of myopia is influenced by a variety of key risk factors, including:



Individual characteristics.

Genetics, ethnicity, and gender play significant roles in the development and progression of myopia.



Lifestyle and environment.

Factors such as educational pressures, increased duration and intensity of study, time spent indoors, and near-work activities are critical influences.

The healthy development of a child's eyes is crucial, not only for their daily activities but also for their long-term future. If a young child's visual system does not function optimally, it can hinder their overall development. This, in turn, can impact their vision-related learning abilities, self-confidence, and ultimately, their capacity to reach their full potential.

We recognize your commitment to providing the best optical support for your young customers, as every detail in their visual experience matters significantly. *We are committed to supporting you.*





Empowering lifelong visual health.



This image was created with Generative AI.



Addressing the global myopia challenge.

ZEISS recognizes that the rising prevalence of myopia represents a significant global health concern, with far-reaching implications for children's quality of life, both today and in the future. In response to this growing myopia pandemic and its long-term ocular health consequences, ZEISS has developed a comprehensive and integrated myopia management ecosystem.

A comprehensive ecosystem: ZEISS Myopia Management Collective.

The ZEISS Myopia Management Collective delivers a portfolio of evidence-based products, solutions, and services, all grounded in robust scientific research and continuous innovation. Designed to support eye care professionals throughout the entire myopia journey, this ecosystem enables proactive, effective, and sustainable myopia management for young patients.

Partnering with ZEISS to advance your practice.

Empowering lifelong visual health through a structured, science-driven approach to myopia management. Collaborating with ZEISS strengthens your practice by combining the credibility of a globally recognized brand with practical support for sustainable business growth. ZEISS provides clinical expertise and professional differentiation through advanced training programs, knowledge sharing, and a comprehensive portfolio of ophthalmic lenses tailored to every stage of life. Complemented by state-of-the-art hardware and software solutions, ZEISS enables you to deliver high-quality, patient-centric care that attracts new patients and fosters long-term loyalty.

Clinically proven myopia management.

At the foundation of effective myopia management are clinically proven interventions. ZEISS equips eye care professionals with validated solutions designed to help control myopia progression in children, supporting improved long-term visual outcomes and reinforcing your role as a trusted partner in pediatric eye care.

Introducing the **ZEISS MyoCare lens portfolio.**

ZEISS MyoCare lenses are a trusted choice for managing myopia, combining innovative design with over a decade of expertise, tailored to address both vision correction and myopia progression. MyoCare® lenses are used in eye care settings in more than 100 countries, from private optometry practices to university hospitals.

Effective myopia management requires a personalized approach due to its multifactorial causes. Treatment options should be based on factors such as age, axial length, progression rate, lifestyle, and environment, ensuring that each patient receives the most suitable care.

Choose ZEISS MyoCare lenses for a comprehensive solution in myopia management.

ZEISS MyoCare lenses utilize an optical strategy that has been shown to slow myopia progression, backed by scientific evidence from **18 peer-reviewed publications.**



Why choose ZEISS MyoCare?
Protection and comfort tailored to a child's lifestyle.

Research indicates a strong link between spectacle lens efficacy and wearing time, recommending full-time wear for optimal outcomes. At ZEISS Vision Care, we understand that effective myopia management in children requires not only slowing progression but also ensuring good vision and comfort.

Our ZEISS MyoCare designs achieve this by offering effortless wear, with children's voices guiding our commitment to comfort and compliance.

Adaptation



>95%

of children adapted to their ZEISS MyoCare or MyoCare S lenses within three days.[4]

Distance vision



92%

of children wearing ZEISS MyoCare or ZEISS MyoCare S confirmed that their distance vision is very good.[4]

Near vision



94%

of children wearing ZEISS MyoCare or ZEISS MyoCare S confirmed that their near vision is very good.[4]

Doing sports, being active



>90%

of children wearing ZEISS MyoCare or ZEISS MyoCare S confirmed that their perception of moving objects, vision while doing sports and going up and down the stairs is very good.[4]

Efficacy confirmed: **Up to 3.5x reduced occurrence of fast myopia progression.**[5]





Clinical trials in Europe and Asia.

Two different multicentre clinical trials in China (NCT 05288335) and Europe (NCT 05919654) demonstrated that ZEISS MyoCare lens designs can help slow myopia progression compared to ZEISS single vision lenses. The rate of progression among children wearing MyoCare® and MyoCare® S lenses was significantly reduced in the first and second years of the clinical trial.

Convincing results.

The 24-month results of the randomized multicentre clinical trial in China show a significant difference in axial length change and spherical equivalent refraction error change between the untreated group wearing single vision lenses and the treatment group wearing ZEISS MyoCare lens design.[1]

Schematic illustration of the ZEISS MyoCare lens design.

What opticians and wearers say about ZEISS MyoCare lenses.

ZEISS MyoCare is our trusted solution for managing myopia, offering proven effectiveness in slowing its progression along with excellent wearability. We greatly appreciate ZEISS's unwavering commitment to scientific rigor and innovation, which has delivered a reliable and effective solution that consistently earns positive feedback from patients and parents alike.
Phil Bullen-Brown, Managing Director, DH Thomas Opticians, 2026.

Clinical experience supported by Myopia Master data shows that MyoCare® lenses effectively slow myopia progression, particularly reflected by stable refraction or minimal myopic progression and reduced axial elongation over time. Serial biometric monitoring confirms sustained control in complaint wearer' Dr Amod.
Dr. Amod Nayak, Ophthalmologist, Dr Agarwals Eye Hospital, 2026.

Since integrating ZEISS MyoCare lenses into my myopia management protocols, I have observed a measurable reduction in myopia progression in a significant proportion of my pediatric patients, together with excellent visual comfort and compliance.
Agathe Lauriol, Orthoptist, North American. Clinic Dubai, 2026.

ZEISS MyoCare lenses represent a myopia management option that is easy to adapt to, clinically effective, and economically accessible for families, making them a valuable addition to pediatric myopia management strategies.
Prof. Nezzar Hachemi, Ophthalmologist, SSMC Abu Dhabi, 2026.

ZEISS MyoCare is an evidence-based myopia management solution, with randomized clinical trial studies indicating a slowing of myopia progression alongside maintained visual comfort. MyoCare® myopia control spectacle lenses provides clinicians with this advanced technology into a comprehensive myopia management strategy.
Prof. Pei-Chang Wu, Director Myopia Prevention and Treatment Center, Kaohsiung Chang Gung Memorial Hospital, Taiwan, 2026.

With its evidence-based design and clinical performance, ZEISS MyoCare has been positively adopted in myopia management for pediatric patients, supporting effective control of myopia progression alongside visual comfort.
Prof. Hui-Ju Lin, Director, Division of Pediatric Ophthalmology Department, Ophthalmic Medical Center, China Medical University Hospital, Taiwan, 2026.



Key features and benefits of the ZEISS MyoCare portfolio.


Creating simultaneous competing defocus.
ZEISS MyoCare represents a new generation myopia management spectacle lenses. The lenses incorporate microstructures that introduce simultaneous competing defocus at the retina retina which are proven to slow the progression of myopia.

ZEISS C.A.R.E. technology
Patented Cylindrical Annular Refractive Elements (C.A.R.E.®) – alternating defocus and correction zones incorporated to the edge of the lens.

ZEISS ClearFocus design
A unique point-by-point, free-form optimized back surface aimed to minimise the hyperopic defocus to maintain the patient's refractive correction as well as the intended myopic defocus for all gaze directions.


Great wearability and acceptance proven.
When worn, ZEISS Myocare and ZEISS Myocare S lenses offer great aesthetics and are comfortable throughout the day, hence allowing children to participate in and enjoy a wide range of their favourite activities.

ZEISS MyoCare lens designs can reduce the occurrence of fast progression **by up to 3.5 times.**[5]



Schematic illustration of the ZEISS MyoCare lens design.

Effective innovation: MyoCare® lens design
ZEISS C.A.R.E. technology and ClearFocus design.



The lens design to slow the progression of myopia in children is built on two pillars:

Front surface.

Patented Cylindrical Annular Refractive Elements, C.A.R.E.® technology – alternating defocus and correction zones in a ring-like pattern on the front surface, expanding towards the edge of the lens. These microstructures deliver a „stop signal" to slow progression of axial elongation.


Back surface.

ZEISS ClearFocus design, the optimized back surface minimizes hyperopic defocus in the periphery of the lens. Both the intended myopic defocus as well as the refractive correction of the patient is maintained for all gaze directions. Supporting the effectivity and wearability of the ZEISS MyoCare lenses.

The combination of a central clear zone and a treatment zone with microstructures, together with the specific back surface design makes ZEISS MyoCare lenses an effective myopia management lens for children within the ZEISS myopia management lens product family.

ZEISS C.A.R.E. technology
The front surface design.

ZEISS MyoCare lens design delivers alternating simultaneous competing defocus and focus areas in the lens periphery through a lens incorporating optical microstructures – C.A.R.E.® technology (Cylindrical Annular Refractive Elements).



- **The central zone (a)** is a circular area around the „zero axis" of the lens providing clear and sharp vision for straight ahead gaze.

- The clear zone is surrounded by the **treatment zone (b)** which expands towards the periphery of the lens. It consists of alternating defocusing elements and regular correction zones.

- The relation of the distribution between these rings is called the **fill factor (c)**, which is 0.5 for all MyoCare® designs. This means there is a ratio of 50:50, balancing the defocus and correction areas and providing the balance for effectivity and wearability.


MyoCare® lens design with optimized parameters for

- **a** The central clear zone
- **b** The treatment zone
- **c** The relation between defocusing and correction zones (fill factor)
- **d** Far distance correction
- **e** Competing myopic defocus
- **f** Central clear vision

ZEISS ClearFocus design
The back surface design.

In contrast to a contact lens, spectacle lenses must consider **movement of the eye behind the lens** to ensure that the **intended correction and myopic defocus** is maintained for all gaze angles.


Conventional spherical single vision lens.



Myopic children wearing conventional **spherical single vision lenses** are exposed to optical abberrations resulting in:

- A hyperopic defocus introduced by the optical aberrations in the lens periphery. Hyperopic defocus is a known trigger for axial elongation and further myopization.

ZEISS MyoCare lens with C.A.R.E.® technology.



ZEISS MyoCare inheres a **point-by-point freeform optimized back surface**, the **ZEISS ClearFocus** design, which ensures that:

- Both the optimal refractive correction and the intended myopic defocus are maintained for all gaze directions.
- Effectively minimizes the induction of hyperopic defocus as opposed to typical spherical single vision lenses.

Explore the MyoCare® portfolio:
ZEISS MyoCare and MyoCare S.



Multicentre RCT in **China**[4]

Multicentre RCT in **Europe**[5]

Schematic illustration of the ZEISS MyoCare and MyoCare S lens design.

ZEISS MyoCare



- **(a)** Central clear zone diameter **7 mm**
- Mean add surface power for micro- structures in the **(b)** treatment zone **+4.6 D**
- Fill factor **0.5**

ZEISS MyoCare S

- **(a)** Central clear zone diameter **9 mm**
- Mean add surface power for micro- structures in the **(b)** treatment zone **+3.8 D**
- Fill factor **0.5**




Effective myopia control interventions depend on their efficacy, wearability, and compliance, which are influenced by factors such as comfort and lifestyle.

Since compliance is key to treatment success, it is important to choose interventions with high wearability.

Prescribing the MyoCare® portfolio

Guidelines on prescribing ZEISS MyoCare lenses.





	When both, MyoCare® and MyoCare® S, are available in your country.	When only MyoCare® is available in your country.
For new patients	Prescribe MyoCare® as the initial lens option for children, irrespective of age.	Prescribe MyoCare® as the initial lens option for children, irrespective of age.
For existing patients	• If the current lens design effectively manages myopia progression in a child, it's advisable to continue with the same design. • If the child experiences adaptation difficulties with MyoCare®, consider switching to MyoCare® S lenses, as they feature a larger central optical zone that may facilitate easier adaptation for the child. If myopia progression remains satisfactory, continue the patient in ZEISS MyoCare S.	

In cases of unsatisfactory myopia management: Consider implementing a combination strategy, such as low-dose atropine, which may yield superior outcomes compared to switching between lens designs.

Availability and customisation.

To ensure clear vision and all-round toughness, coatings for children's lenses must be highly scratch-resistant and durable, as well as dirt, grease and water repellent.

ZEISS DuraVision Plus Kids is the ideal solution with allround protective features. It also offers excellent anti-reflective properties to give your young customers undisturbed vision and low UV reflectance on the back of the lens.

Lenses of the ZEISS MyoCare portfolio are available in / with:



Full UV protection up to 400 nm.
All ZEISS MyoCare and MyoCare S lenses come standard with ZEISS UVProtect technology.



ZEISS DuraVision Plus coatings:

- DuraVision® Plus Platinum UV
- DuraVision® Plus Silver UV
- DuraVision® Plus BlueProtect UV
- DuraVision® Plus Chrome UV
- DuraVision® Plus Kids



A wide range of plastic lens materials and indices: polycarbonate (1.59), 1.50, 1.60 and 1.67 (Also available as stock lenses in polycarbonate).


Please adjust as per availability in your market.

ZEISS services enabling you to move faster.
Turn innovation into everyday sucess.



Helping your practice stand out.

Enhance your visibility with compelling marketing assets and content, helping you attract new customers for myopia care. We engage younger audiences and families, creating experiences that set your practice apart from the rest.



Kids communication.

Introducing Pupillo, the friendly mascot of the ZEISS Myopia Management Collective, designed to facilitate effortless communication with children. Pupillo and his friends are crafted to engage and inspire young audiences in pre-school and primary school, enhancing awareness about myopia and its associated risks. Pupillo ensures high recognition value both in-store and beyond. Supporting materials are available in both print and digital formats.



Expanding your knowledge.

Empower your team with extensive, in-depth information on myopia and its progression. Our comprehensive training covers extensive expertise in holistic evaluation, myopia tracking and treatment options.



Supporting your growth.

Leverage our ZEISS Myopia Management Business Solutions to optimize your practice, improve patient outcomes and offer effective myopia care. We provide the resources and expertise you need to succeed in this evolving landscape.

ZEISS Myopia Management Collective

To support you at every stage of the myopia journey.



Interventions.

ZEISS offers a robust portfolio of myopia management interventions to address diverse needs in slowing myopia progression and enhancing eye health. Our solutions empower professionals to provide tailored care for children, recognizing that no single approach fits all.

Workflow solutions.

ZEISS myopia management workflow solutions to enhance consultations, improve patient experiences, and strengthen market positioning. These tools build trust and loyalty, leading to better myopia management outcomes.





Marketing.

ZEISS is committed raising awareness among parents and children by providing essential information through Myopia Management Marketing. We aim to establish ourselves as a trusted partner with eye care and healthcare professionals, ensuring that consumers actively seek ZEISS for their myopia care needs.

Training enablement.

ZEISS training builds confidence, enabling your team to deliver exceptional vision care. Engaging training sessions keeps staff aligned and informed. Our training modules equip professionals with the knowledge and skills for effective management.



Business enablement.

ZEISS wants to empower you by offering support to enhance your business operations with Myopia Management Business Solutions.



Need more support?

Contact your ZEISS representative.

Optional field for contact details.

References

[1] Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016 May;123(5):1036–42.
[2] World report on vision. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
[3] Sankaridurg P, Tahhan N, Kandel H, et al. IMI Impact of myopia. Invest Ophthalmol Vis Sci. 2021;62(5):2. https://doi.org/10.1167/iovs.62.5.2.
[4] Two-year prospective, multi-center, double-blind, randomized controlled clinical trial lead by Tianjin Eye Hospital Optometric Center, China, 2022, on 80 myopic children wearing ZEISS MyoCare Rx lenses, 80 myopic children wearing ZEISS MyoCare S Rx lenses and 80 myopic children wearing ZEISS Single Vision lenses.
[5] Percentage of individual study participants that showed more than 0.75D progression in SE between baseline and the 12month follow-up wearing ZEISS MyoCare lens designs vs SV lenses. Sankaridurg, P., et al. (2024, May 5–9). Probability of surviving fast progression and eye growth reversal after 1-year of spectacle wear with cylindrical annular refractive elements [Conference presentation abstract]. The Association for Research in Vision and Opthalmology (ARVO) Annual Meeting, Seattle, WA, United States.
[6] Two-year prospective, multi-center, double-blind, randomized controlled clinical trial lead by Institute of Education and Sciences (ISEC), Portugal, 2023, on 115 myopic children wearing ZEISS MyoCare Rx lenses and 119 myopic children wearing ZEISS Single Vision lenses. 12-months interim results published in Ophthalmic and Physiological Optics in 2025.

Carl Zeiss

Xxxxxxxxxxxxxxxxxxxx
12345 Xxxxxxxxxxxx

Phone: 123 456 789
Fax: 123 456 789

Email: xxxxxx@zeiss.xx
www.zeiss.de/xxxxxxxxxxxxxxxx

EN_002700411 Printed in Germany CZ-xx/20xx

Subject to change in design and scope of delivery and as a result of ongoing technical development.